Head-to-head clinical analysis & difference comparison: details on mechanism of action, dosing, half-life, interactions, and maternal-fetal safety.
PLENVU vs MISOPROSTOL
Clinician-reviewed, head-to-head comparison of mechanism, dosing, pharmacokinetics, and safety profiles.
Last clinically reviewed: July 2026 · OpiCalc Medical Review Team
PLENVU is an osmotic laxative that induces bowel cleansing by causing water retention in the colon, leading to increased intraluminal pressure and stimulation of peristalsis. Its components (polyethylene glycol 3350, sodium ascorbate, ascorbic acid, sodium sulfate) act synergistically to produce a cathartic effect.
Misoprostol is a synthetic prostaglandin E1 analog that induces uterine contractions and cervical ripening by binding to prostaglandin receptors, leading to increased intracellular calcium and myometrial contraction. It also inhibits gastric acid secretion by reducing parietal cell activity and protecting gastric mucosa via increased bicarbonate and mucus production.
FDA-approved: Bowel cleansing prior to colonoscopy in adults.,Off-label: Bowel preparation for colorectal surgery or other procedures requiring colonic cleansing.
Prevention and treatment of NSAID-induced gastric ulcers,Medical abortion (with mifepristone or methotrexate),Cervical ripening and induction of labor,Management of postpartum hemorrhage,Off-label: Missed abortion, intrauterine fetal death, incomplete abortion
2 sachets (each containing ascorbic acid 4.7g, macrogol 3350 52.5g, sodium ascorbate 5.9g, sodium sulfate 3.75g) dissolved in water to a total volume of 500m L, administered orally as a split-dose regimen: first dose (2 sachets in 500m L water) at 6-9 pm on the day before colonoscopy, followed by additional 500m L of clear fluids; second dose (2 sachets in 500m L water) on the morning of colonoscopy, completed at least 2 hours before the procedure, followed by additional 500m L of clear fluids.
200 mcg orally four times daily (with meals and at bedtime) for prevention of NSAID-induced gastric ulcers; 800 mcg sublingually every 4 hours for up to 3 doses for labor induction; 25 mcg orally single dose for cervical ripening.
Not applicable (non-absorbed agent); systemic absorption is minimal, so no terminal half-life is defined.
2-3 hours for misoprostol acid (active metabolite); clinically, a short duration requires multiple daily dosing. In patients with renal impairment, half-life may be prolonged but not significantly clinically.
Polyethylene glycol 3350 is minimally absorbed and eliminated unchanged in feces. Ascorbic acid and sodium ascorbate are absorbed and metabolized via normal pathways (e.g., oxidation, conjugation). Sodium sulfate is absorbed and excreted primarily in urine.
Hepatic, primarily via de-esterification to misoprostol acid (active metabolite), which undergoes further oxidation and reduction; CYP450 minimal involvement; metabolites excreted renally.
Primarily fecal (90-95%) as unabsorbed drug; renal excretion is negligible (<1%).
Primarily renal excretion of metabolites; ~80-90% of a radiolabeled dose is excreted in urine within 24 hours, with the remainder in feces. Misoprostol acid (active metabolite) undergoes further beta-oxidation and reduction; <1% excreted unchanged.
<5% bound to plasma proteins (due to minimal absorption).
80-89% bound to albumin (specifically to human serum albumin). Binding is saturable at high concentrations.
Not applicable (confined to GI tract; systemic Vd not measurable).
Apparent Vd of misoprostol acid: approximately 0.3-0.5 L/kg. This indicates distribution primarily into extracellular fluid; low tissue binding.
Oral: <0.1% systemically available due to lack of absorption.
Oral: ~60% (rapid and extensive first-pass metabolism to misoprostol acid); Vaginal/buccal/sublingual: bioavailability is higher (~70-80%) due to partial avoidance of first-pass metabolism.
Contraindicated in patients with estimated glomerular filtration rate (e GFR) < 30 m L/min/1.73 m² due to risk of acute phosphate nephropathy. No dose adjustment recommended for e GFR ≥ 30 m L/min/1.73 m².
No dose adjustment required for GFR > 30 m L/min; for GFR 10-30 m L/min, consider reducing oral dose by 50% if GI adverse effects occur; for GFR < 10 m L/min, use with caution and monitor for toxicity.
No specific dosage adjustment based on Child-Pugh classification is provided by the manufacturer. Use with caution in patients with severe hepatic impairment due to potential electrolyte disturbances.
Child-Pugh A: No adjustment; Child-Pugh B: No data, use with caution; Child-Pugh C: Not studied, avoid use.
Not approved for use in pediatric patients (age < 18 years). Safety and efficacy not established.
Safety and efficacy not established for most indications; for congenital heart disease with NSAID-induced ulcer risk, limited data suggest 2-5 mcg/kg/dose orally four times daily (max 200 mcg/dose).
No specific dose adjustment required for elderly patients, but caution is advised due to increased risk of dehydration, electrolyte abnormalities, and renal impairment. Ensure adequate hydration and monitor renal function.
Start at lower end of dosing range (e.g., 100 mcg orally four times daily) due to increased risk of diarrhea and hypotension; titrate slowly based on tolerance.
No FDA black box warning.
Misoprostol is contraindicated in pregnant women for the prevention of NSAID-induced gastric ulcers because it can cause abortion. If used for induction of labor or abortion, careful patient selection and monitoring are required. It may cause uterine hyperstimulation, leading to fetal distress, uterine rupture, or maternal death.
Serious fluid and electrolyte abnormalities (e.g., hyponatremia, hypokalemia, seizures).,Cardiac arrhythmias in patients with electrolyte imbalances or prolonged QT interval.,Renal impairment: Risk of acute tubular necrosis and nephrocalcinosis.,Mucosal ulceration or colitis (rare).,Sulfate absorption may cause metabolic acidosis in susceptible patients.
Uterine hyperstimulation and rupture (especially with prior uterine surgery or grand multiparity),Fetal distress and meconium passage,Maternal hypotension and tachycardia,Gastrointestinal effects (diarrhea, abdominal pain),Avoid in pregnancy for peptic ulcer disease indication,Not to be used as a cervical ripener in patients with uterine scar or fetal distress
Gastrointestinal obstruction or ileus.,Perforation of the gastrointestinal tract.,Gastric retention or gastroparesis.,Toxic colitis or toxic megacolon.,Known hypersensitivity to any component of PLENVU.
Pregnancy (for ulcer prevention; used intentionally for abortion/labor induction under specific protocols),Hypersensitivity to misoprostol or prostaglandins,History of cesarean section or major uterine surgery (relative for labor induction),Placenta previa or vasa previa,Active genital herpes or pelvic inflammatory disease (relative for abortion)
Avoid solid foods, dairy products, and any colored liquids (especially red, purple, or orange) during preparation. Patients must consume only clear liquids (e.g., water, clear broth, apple juice, clear gelatin, black coffee or tea without milk) to maintain hydration. Alcohol should be avoided due to dehydrating effects and potential interaction with preparation.
No specific food interactions. Avoid magnesium-containing antacids as they may worsen diarrhea. Take with food to reduce gastrointestinal upset.
PLENVU (polyethylene glycol 3350, sodium ascorbate, sodium sulfate, ascorbic acid, and macrogol) is classified as FDA Pregnancy Category C. There are no adequate and well-controlled studies in pregnant women. In animal studies, no evidence of teratogenicity was observed at doses up to 2 times the maximum recommended human dose. However, the osmotic laxative effect may cause fluid and electrolyte shifts, potentially affecting fetal perfusion. Use during pregnancy should be reserved for cases where bowel cleansing is essential and benefits outweigh risks, particularly in the first trimester due to theoretical concerns of dehydration or electrolyte imbalance.
Misoprostol is a prostaglandin E1 analogue that stimulates uterine contractions and causes cervical ripening. It is contraindicated in pregnancy due to its abortifacient properties. First trimester exposure may cause uterine rupture, fetal death, or congenital anomalies (e.g., Möbius syndrome, limb defects). Second and third trimester use is limited to induction of labor or abortion; risks include uterine hyperstimulation, fetal distress, and meconium passage. Post-term effects: none specified.
It is unknown whether PLENVU or its components are excreted in human breast milk. Polyethylene glycol is poorly absorbed systemically after oral administration, suggesting minimal transfer into breast milk. However, because many drugs are excreted in human milk, caution should be exercised when PLENVU is administered to a nursing woman. The M/P ratio has not been established for this combination product. Consider the developmental and health benefits of breastfeeding along with the mother's clinical need for PLENVU.
Misoprostol is excreted into breast milk in small amounts (M/P ratio 1.0-1.4). No adverse effects in nursing infants have been reported. However, caution is advised when used postpartum for hemorrhage due to potential diarrhea in the infant. Alternative agents may be preferred.
No specific dosing adjustments are recommended for PLENVU in pregnancy; however, clinical trials excluded pregnant women. The standard dose (two sachets: split-dose regimen) should be used cautiously with close monitoring for dehydration and electrolyte imbalances. Pharmacokinetic changes in pregnancy (increased volume of distribution, altered GI motility) may affect drug dispersal, but no formal studies exist. Consider reducing fluid volume if contraindicated, but no dose reduction has been established.
Pharmacokinetics in pregnancy: No significant changes in absorption or clearance require dose adjustment. However, dosing regimens differ by indication (e.g., 200-600 mcg for labor induction vs. 400-800 mcg for abortion). No standard dose reduction is needed; dose is based on gestational age and clinical response.
PLENVU is a polyethylene glycol (PEG)-based bowel preparation used for colonoscopy. Adequate hydration is critical to prevent electrolyte abnormalities; ensure patients drink additional clear fluids as directed. Split-dose regimen (half dose evening before, remainder morning of procedure) improves tolerance and colon cleansing. Caution in patients with renal impairment, CHF, or electrolyte disturbances; monitor for volume depletion. Not recommended in patients with GI obstruction, ileus, or toxic colitis. May reduce absorption of oral medications (e.g., contraceptives, antidiabetics, anticoagulants); advise temporal separation.
Misoprostol is a synthetic prostaglandin E1 analog used off-label for cervical ripening and labor induction, and for medical abortion in combination with mifepristone. It is also used for prevention of NSAID-induced gastric ulcers. For obstetric indications, it can be administered orally, sublingually, vaginally, or buccally, with dosing and route varying by protocol. Onset of action for cervical ripening is 6-8 hours. Contraindicated in pregnancy for ulcer prophylaxis due to abortifacient properties; must be used with caution in women of childbearing age. Common side effects include diarrhea, abdominal pain, and nausea. Misoprostol should not be given simultaneously with magnesium-containing antacids as they may worsen diarrhea.
Take PLENVU exactly as prescribed; follow the split-dose regimen for best results.,Drink the full amount of clear liquids recommended (including water) to prevent dehydration.,Avoid solid foods, dairy, red/purple liquids, and alcohol during preparation.,Expect frequent, watery bowel movements; stay near a bathroom.,If you miss a dose, consult your healthcare provider; do not double the dose.,Inform your doctor about all medications you take, especially diabetes meds, blood thinners, and diuretics.,Stop taking oral medications (e.g., contraceptives, hypoglycemics) as directed during prep; discuss alternative contraception.,Seek medical help if you experience severe vomiting, dizziness, fainting, or signs of allergic reaction.
Take misoprostol exactly as prescribed; do not increase dose or frequency.,For ulcer prevention: take with food and at bedtime, and avoid taking with antacids containing magnesium.,If you are pregnant or could become pregnant, do not use misoprostol for ulcer prevention; it may cause miscarriage or birth defects.,Report severe diarrhea, abdominal pain, or vaginal bleeding to your healthcare provider.,For abortion or labor induction: discuss the full treatment plan and expected symptoms with your doctor.,Do not share this medication with others.
No interactions on record
"The combination of sodium bicarbonate and misoprostol may lead to an increased risk of hypernatremia and fluid overload. Sodium bicarbonate, an alkalinizing agent, can cause sodium retention and volume expansion, while misoprostol, a prostaglandin analog used to prevent NSAID-induced ulcers, can enhance fluid absorption in the gastrointestinal tract, potentially exacerbating electrolyte disturbances and fluid imbalance. This interaction is particularly concerning in patients with compromised renal function or cardiovascular disease."
"Olopatadine, an antihistamine with anticholinergic properties, may diminish the efficacy of misoprostol, a synthetic prostaglandin E1 analog used for cervical ripening and induction of labor. The potential antagonism arises from olopatadine's inhibition of prostaglandin-mediated smooth muscle contraction and mucus secretion. This interaction could lead to reduced misoprostol effectiveness, resulting in inadequate cervical ripening or failure of labor induction."
"Concurrent use of bismuth subcitrate potassium and misoprostol may result in additive gastrointestinal toxicity, including increased risk of diarrhea, abdominal cramping, and potential mucosal irritation. Misoprostol, a prostaglandin E1 analog, stimulates intestinal secretion and motility, while bismuth compounds can cause blackening of the stool and occasional gastrointestinal distress. The combined effect can lead to more pronounced adverse effects without therapeutic benefit, particularly in patients with inflammatory bowel disease or diarrhea-predominant conditions."
Explore head-to-head clinical comparisons of other medications in the same therapeutic classes.
Common clinical questions about PLENVU vs MISOPROSTOL, answered by our medical review team.
PLENVU is a Osmotic Laxative that works by PLENVU is an osmotic laxative that induces bowel cleansing by causing water retention in the colon, leading to increased intraluminal pressure and stimulation of peristalsis. Its components (polyethylene glycol 3350, sodium ascorbate, ascorbic acid, sodium sulfate) act synergistically to produce a cathartic effect.. MISOPROSTOL is a Prostaglandin Analog that works by Misoprostol is a synthetic prostaglandin E1 analog that induces uterine contractions and cervical ripening by binding to prostaglandin receptors, leading to increased intracellular calcium and myometrial contraction. It also inhibits gastric acid secretion by reducing parietal cell activity and protecting gastric mucosa via increased bicarbonate and mucus production.. They differ in pharmacokinetic profiles, FDA-approved indications, and side effect profiles.
Potency comparisons between PLENVU and MISOPROSTOL depend on the specific clinical indication. These are agents from distinct pharmacological classes and are not directly interchangeable by dose. A physician or clinical pharmacist should guide any therapeutic switching decisions.
The standard adult dose of PLENVU is: 2 sachets (each containing ascorbic acid 4.7g, macrogol 3350 52.5g, sodium ascorbate 5.9g, sodium sulfate 3.75g) dissolved in water to a total volume of 500m L, administered orally as a split-dose regimen: first dose (2 sachets in 500m L water) at 6-9 pm on the day before colonoscopy, followed by additional 500m L of clear fluids; second dose (2 sachets in 500m L water) on the morning of colonoscopy, completed at least 2 hours before the procedure, followed by additional 500m L of clear fluids.. The standard adult dose of MISOPROSTOL is: 200 mcg orally four times daily (with meals and at bedtime) for prevention of NSAID-induced gastric ulcers; 800 mcg sublingually every 4 hours for up to 3 doses for labor induction; 25 mcg orally single dose for cervical ripening.. Dosing should always be individualized based on indication, renal and hepatic function, age, and other patient factors.
No direct drug-drug interaction has been formally documented between PLENVU and MISOPROSTOL in current clinical databases. However, individual patient risk factors including other medications, organ function, and comorbidities should always be evaluated by a qualified healthcare provider.
The maternal-fetal safety profiles differ. PLENVU is classified as Category C. PLENVU (polyethylene glycol 3350, sodium ascorbate, sodium sulfate, ascorbic acid, and macrogol) is classified as FDA Pregnancy Category C. There are no adequate and well-controlle. MISOPROSTOL is classified as Category D/X. Misoprostol is a prostaglandin E1 analogue that stimulates uterine contractions and causes cervical ripening. It is contraindicated in pregnancy due to its abortifacient properties. Always consult a maternal-fetal medicine specialist before taking either drug during pregnancy or lactation.